Competing Autocrine Pathways Involving Alternative Neuropilin-1 Ligands Regulate Chemotaxis of Carcinoma Cells


Division of Cancer Biology and Angiogenesis, Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215

Abstract

Neuropilin-1 (NP1), in conjunction with plexins, promotes axon repulsion by binding to semaphorin 3A (SEMA3A). Although NP1 is expressed in carcinoma cells, its functions have remained elusive, and neither SEMA3A nor plexin expression has been explored in cancer. Here we provide evidence that breast carcinoma cells support an autocrine pathway involving SEMA3A, plexin-A1, and NP1 that impedes their ability to chemotax. Reducing SEMA3A or NP1 expression by RNA interference or inhibiting plexin-A1 signaling enhanced migration. Conversely, expression of constitutively active plexin-A1 impaired chemotaxis. The paradox of how breast carcinoma cells expressing these endogenous chemotaxis inhibitors are able to migrate is explained by their expression of vascular endothelial growth factor (VEGF), a NP1 ligand that competes with SEMA3A for receptor binding. Finally, we establish that the ratio of endogenous VEGF and SEMA3A concentrations in carcinoma cells determines their chemotactic rate. Our findings lead to the surprising conclusion that opposing autocrine loops involving NP1 regulate the chemotaxis of breast carcinoma cells. Moreover, our data indicate a novel autocrine function for VEGF in chemotaxis.

Introduction

In addition to the classical VEGF3 tyrosine kinase receptors, KDR and Flt-1, NP1 serves as a high-affinity VEGF receptor (1). NP1 expression on endothelial cells enhances VEGF signaling by increasing the affinity of VEGF for the classical VEGF receptor tyrosine kinase KDR (1). Interestingly, NP1 expression has also been reported in a variety of tumors in the absence of KDR or Flt-1 (1, 2). On the basis of the established importance of VEGF in tumor progression, our previous studies investigated a role for NP1 in carcinoma cells as a VEGF receptor, in the absence of classical VEGF receptor tyrosine kinases. These studies indicated that NP1 supports a VEGF autocrine signaling pathway that is critical for breast carcinoma cell survival (2).

Of note, NP1 was identified originally in neurons as a receptor for SEMA3A, a soluble member of the semaphorin family that performs a critical role in axon guidance (3, 4). The ability of NP1, which lacks consensus signaling domains, to deliver SEMA3A-associated chemorepulsive signals is dependent on NP1 associations with plexins, proteins displaying Met homologies (5, 6). Although functions for NP1 as a VEGF receptor in tumor cells have been reported (2, 7), the possibility that NP1 influences tumor function by supporting signaling through its alternative ligand, SEMA3A, has not been examined. Here, we provide the first evidence for expression of SEMA3A and plexin-A1 in carcinoma cells and demonstrate that these molecules are autocrine inhibitors of breast carcinoma migration. Importantly, we also identify a novel function for VEGF in carcinoma cell migration involving its inhibition of SEMA3A activity.

Materials and Methods

mRNA Detection. mRNA was purified from the indicated cell lines using the RNeasy kit (Qiagen) according to the manufacturer’s recommended protocol. RNA (2 μg) was added to RT-PCR reactions containing the indicated primers at a concentration of 0.6 μM. Alternatively, cDNA was generated from carcinoma cells purified from human breast tumors (provided by K. Polyak, Dana-Farber Cancer Institute). The conditions for amplifying SEMA3A and NP1 cDNA were as follows: 35 cycles, 95°C, 15 min; 95°C, 30 s; 55°C, 1 min; and 72°C, 1 min, followed by a 72°C, 10-min final extension step. The conditions for amplifying plexin-A1 cDNA were as follows: 35 cycles, 95°C, 15 min; 95°C, 30 s; 58°C, 1 min; and 72°C, 2.5 min, followed by a 72°C, 10-min final extension step. The sequences of amplification primers are as follows: SEMA3A Forward, GACCTTTCGATCTTCCGAACTCTTGGC; SEMA3A Reverse, GCTATACTACAACGGCTATCCCTTG; NP1 Forward, ATGGAGAGGGGTCCGCG; NP1 Reverse, CTATCGGCGTGCCTGGTGTA; Plexin-A1 Forward, GAGGATGGCCACATGCTGCTTG; and Plexin-A1 Reverse, AGGCGCTATGGGACGACCG.

RNAi Transient Transfections. RNAis were designed and synthesized by Dharmaco, Inc. (see below for sequences). Cells at 60% confluence were transfected in penicillin/streptomycin-free medium with the indicated RNAi using TRO lipid (Mirus), following the manufacturer’s recommended protocol. The following RNAi concentrations were determined to be optimal for inhibiting protein expression: 200 nm RNAi for all cell lines; 200 nm SEMA3A RNAi for MDA-231 cells; 100 nm SEMA3A RNAi for MDA-435 and MCF-7 cells. After 20 h, RNAis were removed, and the cells were maintained in complete medium with the indicated antibodies for an additional 24 h: NP1 RNAi, GAGGAGGUCUGCAGUUCC; Scrambled NP1 control, AGAGAGAUGGUCGUGCUG; SEMA3A RNAi: AAAGUUAUAAUGCC; Scrambled SEMA3A control, AGAGAGAUGGUCGUGCUG; and Scrambled SEMA3A control, AGAGAGAUGGUCGUGCUG.

SEMA3A and SCR SEMA3A RNAi Retrovirus Generation. To create SEMA3A-pSUPER and SCR SEMA3A-pSUPER expression vectors, the following oligonucleotides (Invitrogen, Grand Island, NY) were cloned into pSUPER (a gift from R. Agami, The Netherlands Cancer Institute, Amsterdam, the Netherlands): SEMA3A, 5'-gatctcgcGATGTTGATGAGCTATAATGATTTTTTgggaaas-3' and 5'-agttctccaaagAGTTCATTAGTGCCCACCTTcaaaagagcaatggagtagagttaggtgagccacatagattggctttgagcag-3'; SCR SEMA3A, 5'-gatctcgcGATGTTGATGAGCTATAATGATTTTTTgggaaas-3' and 5'-agttctccaaagAGTTCATTAGTGCCCACCTTcaaaagagcaatggagtagagttaggtgagccacatagattggctttgagcag-3'; EcoRI- and Xhol-digested inserts containing the H1-RNA promoter and targeting oligonucleotides from pSUPER were then subcloned into pSUPER.retro (Oligoengine, Seattle, WA). All plasmids were sequenced to confirm that they were correct. To generate retroviruses, SEMA3A-pSUPER or SCR SEMA3A-pSUPER.

Received 4/9/03; revised 6/2/03; accepted 6/13/03.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by NIH Grants CA89209 (to A. M. M.) and CA93855 (to R. E. B.).

2 To whom requests for reprints should be addressed, at Division of Cancer Biology and Angiogenesis, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215. Phone: (617) 667-1449; Fax: (617) 667-3616; E-mail: rbacheld@caregroup.harvard.edu.

3 The abbreviations used are: VEGF, vascular endothelial growth factor; NP1, neuropilin-1; SEMA3A, semaphorin 3A; RNAi, RNA interference; ZVAD-FMK, benzoyloxycarbonyl-VAD-fluoromethyl ketone; β-gal, β-galactosidase; VSV, vesicular stomatitis virus; AS, antisense.

5230

Downloaded from cancerres.aacrjournals.org on January 13, 2018. © 2003 American Association for Cancer Research.
Results and Discussion

Given that NP1 is expressed in breast carcinoma cell lines (Refs. 1 and 2; Fig. 1A) and tumors (Fig. 1A), we assessed the potential involvement of this receptor in carcinoma chemotaxis. Surprisingly, a NP1-neutralizing antibody increased the chemotaxis of MDA-231 cells toward NIH 3T3 conditioned medium 2-fold (Fig. 1B). To confirm and extend this finding, we implemented an RNAi strategy to confirm and extend this finding, we implemented an RNAi strategy to diminish NP1 expression in each of three breast carcinoma cell lines. Our previous data indicate that NP1 is essential for breast carcinoma survival because it supports VEGF autocrine survival signaling (2). To evaluate the role of NP1 in migration separately from its requirement for breast carcinoma cell survival (2), NP1 RNAi transfections were performed in the presence of the general caspase inhibitor, ZVAD-FMK. Under these conditions, the inhibition of NP1 expression did not impact cell survival (Fig. 1C). Of note, this RNAi abolished NP1 expression in MDA-435 and MDA-231 cells, and it increased their chemotaxis by 1.5- and 2.3-fold, respectively (Fig. 1C). In addition, this RNAi reduced NP1 expression in MCF-7 cells, a poorly migratory breast carcinoma line, and enhanced their chemotaxis 5-fold (Fig. 1C).

SEMA3A inhibits axon growth by binding to NP1 and the NP1 coreceptor, plexin-A1 (5, 6). On the basis of our finding that NP1 is inhibitory for breast carcinoma migration, we hypothesized that these cells express SEMA3A and plexin-A1. In fact, SEMA3A and plexin-A1 mRNA were detected in each of three breast carcinoma cell lines, as well as in primary breast tumors (Figs. 2A and 3A). We also identified SEMA3A and plexin-A1 protein by immunoblotting proteins extracted from these samples with a SEMA3A- or plexin-A1-specific antibody (Figs. 2A and 3A). To elucidate a function for SEMA3A in breast carcinoma cells, we reduced SEMA3A expression using a SEMA3A RNAi. This RNAi, which reduced SEMA3A expression significantly (Fig. 2B), increased the migration of these cells (Fig. 2B) without influencing cell survival (data not shown). To assess the importance of plexin-A1 in migration, MDA-231 cells were transfected with a plexin-A1 cytoplasmic domain deletion mutant that inhibits SEMA3A signaling (6). Expression of this mutant in MDA-231 cells enhanced their migration significantly (Fig. 3B). Conversely, expression of a semaphorin homology domain deletion mutant of plexin-A1 that exhibits constitutive activity in neurons (9) inhibited MDA-231 migration (Fig. 3C). None of these reagents influenced cell survival in the presence of ZVAD-FMK (Fig. 3, B and C). These data indicate that an autocrine pathway involving...

Fig. 1. NP1 suppresses chemotaxis of breast carcinoma cells. A: top panel, NP1-specific RT-PCR reactions were performed using the indicated mRNAs; middle panel, protein extracts were immunoblotted with the indicated antibodies (mouse anti-NP1 and rabbit anti-Stat1; Santa Cruz Biotechnology); bottom panel, NP1 was PCR amplified from cDNA obtained from carcinoma cells isolated from breast tumors. B, MDA-231 cells were incubated for 6 h (+ ZVAD-FMK) with either a rabbit IgG or NP1-specific polyclonal antibody (Ab; provided by Alex Kolodkin, Johns Hopkins University School of Medicine, Baltimore, MD), and their chemotaxis toward conditioned 3T3 medium was assessed in a 3-h assay in the continued presence of antibody (+ ZVAD-FMK). C, cells were transfected with a scrambled (Scr) or NP1-specific RNAi, and their ability to migrate toward conditioned 3T3 medium was assessed in a 24-h (MCF7), 15-h (MDA-435), or 3-h (MDA-231) assay. The mean number (bars, ±SD) of migrated cells from two wells (four fields/well) is indicated. * P < 0.02 in a Student’s t test. Inhibition of NP1 expression by NP1 RNAi was assessed by immunoblotting, as described in A. The percentage of apoptotic cells was assessed using Annexin V-FITC, as described previously (17). Similar results were observed in three independent experiments.
SEMA3A, NP1, and plexin-A1 impede the chemotaxis of breast carcinoma cells. Our ability to increase breast carcinoma migration by expressing a dominant-negative plexin-A1 suggests that other plexins, if expressed in these cells, cannot support SEMA3A signaling in the absence of plexin-A1 function.

Genes that are inhibitory for cell growth are frequently subject to chromosomal deletion, mutational inactivation, or gene silencing in tumor cells (10–12). The ability of breast carcinoma cells to migrate and invade, despite their expression of molecules involved in SEMA3A signaling, suggested that they support a novel mechanism for repressing SEMA3A function. Increased VEGF expression is a hallmark of breast carcinoma progression (13, 14). Until recently, the function of VEGF in tumor progression was thought to relate solely to its angiogenic activity. We were intrigued by the reported ability of recombinant VEGF and recombinant SEMA3A, which exhibit similar affinities for NP1 and NP1/plexin complexes, respectively (1, 5), to compete for NP1 binding (15, 16). On the basis of these findings, we postulated that endogenous VEGF and SEMA3A compete for NP1 binding, and that the ratio of the concentration of these proteins in carcinoma cells is a critical determinant of their chemotactic rate. To determine this ratio, we measured the relative amounts of SEMA3A and VEGF protein in these cells (Fig. 4A). We then compared the ratio of these concentrations to the relative chemotactic rate of these carcinoma cells. As shown in Fig. 4B, MCF-7 cells, which exhibited the lowest chemotactic rate, displayed the highest ratio of SEMA3A to VEGF protein. MDA-435 cells, which were more chemotactic than MCF-7 cells, demonstrated a lower SEMA3A:VEGF concentration ratio (Fig. 4B). The lowest SEMA3A:VEGF ratio was observed in...
MDA-435 cells were infected with retroviruses expressing either a SEMA3A-specific or scrambled RNAi (control). Stable infectants that expressed SEMA3A RNAi exhibited a significant decrease in SEMA3A expression relative to cells infected with the control retrovirus (Fig. 4D). These infectants were then transfected transiently with either the VEGF AS or control oligonucleotide. Confirming the data in Fig. 4C, VEGF expression in VEGF AS transfecteds was reduced by 50%. We then determined the ability of these cells to chemotax toward conditioned NIH 3T3 medium. Confirming the data in Fig. 4C, the chemotaxis of cells infected with the control retrovirus was significantly reduced by VEGF AS transfection. Strikingly, the migration of VEGF AS transfecteds was restored upon reducing SEMA3A expression with the SEMA3A RNAi-expressing retrovirus. In the presence of ZVAD-FMK, we did not observe an effect of reducing either SEMA3A or VEGF expression on cell survival (data not shown). These data identify VEGF and SEMA3A as antagonistic, autocrine NPI ligands that regulate breast carcinoma migration.

Acknowledgments

We thank Drs. A. Kolodkin, H. Fujisawa, S. Strittmatter, P. Comoglio, and K. Polyak for valuable reagents. In addition, we thank A. Dugan for excellent technical assistance and Drs. J. Chung, K. Simpson, A. Kolodkin, and D. Senger for valuable discussion.

References

## Cancer Research

**Running Head**: Neuropilin-1 Ligands Regulate Chemotaxis of Carcinoma Cells

### Competing Autocrine Pathways Involving Alternative Neuropilin-1 Ligands Regulate Chemotaxis of Carcinoma Cells

Robin E. Bachelder, Elizabeth A. Lipscomb, Xuena Lin, et al.


<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: <a href="http://cancerres.aacrjournals.org/content/63/17/5230">http://cancerres.aacrjournals.org/content/63/17/5230</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cited articles</td>
<td>This article cites 17 articles, 6 of which you can access for free at: <a href="http://cancerres.aacrjournals.org/content/63/17/5230.full#ref-list-1">http://cancerres.aacrjournals.org/content/63/17/5230.full#ref-list-1</a></td>
</tr>
<tr>
<td>Citing articles</td>
<td>This article has been cited by 26 HighWire-hosted articles. Access the articles at: <a href="http://cancerres.aacrjournals.org/content/63/17/5230.full#related-urls">http://cancerres.aacrjournals.org/content/63/17/5230.full#related-urls</a></td>
</tr>
</tbody>
</table>

### E-mail alerts

Sign up to receive free email-alerts related to this article or journal.

### Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

### Permissions

To request permission to re-use all or part of this article, use this link [http://cancerres.aacrjournals.org/content/63/17/5230](http://cancerres.aacrjournals.org/content/63/17/5230). Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.